Atara Biotherapeutics has started a Phase 1 clinical trial to assess ATA188’s safety and potential to treat progressive or relapsing-remitting multiple sclerosis.
ATA188 is the company’s next-generation T-cell immunotherapy. ... Read more
Nektar Therapeutics has started a Phase 1 clinical trial of its biologic therapy NKTR-358 for inflammatory disorders and autoimmune diseases like multiple sclerosis. NKTR-358 is a first-in-class regulatory ... Read more
In a new study entitled “The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients,” a team of scientists discovered that ... Read more
Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s ... Read more
Pin It on Pinterest